Compare Amphastar Pharmaceuticals Inc (AMPH) vs Omnicom Group Inc. (OMC) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Omnicom Group (OMC) trades at $81.93, up 1.36% on the day, with a bullish technical outlook driven by moving averages and a consensus analyst price target of $105.75. The company reported revenue of $17.27 billion in 2025, though net income was negative $54.5 million, reflecting margin pressure. Recent news highlights major client wins, including IBM and Netflix partnerships, and strong free cash flow generation of $2.94 billion from operations.

OMC presents a value opportunity with a low P/E of 12.16 and positive earnings beats in recent quarters, but faces risks from intense competition and fluctuating profitability. The stock's upside potential is supported by analyst optimism and strategic expansions in AI and streaming advertising, though investors should monitor margin recovery and debt levels.